このページの翻訳は実験的なもので、現在開発中です。お待ちしております！

Viridian Therapeutics 将来の成長

Future 基準チェック /26

Viridian Therapeuticsは、48.3%と67.9%でそれぞれ年率48.3%で利益と収益が成長すると予測される一方、EPSはgrowで48.3%年率。

主要情報

48.3%

収益成長率

48.3%

EPS成長率

Biotechs 収益成長	24.6%
収益成長率	67.9%
将来の株主資本利益率	n/a
アナリストカバレッジ	Good
最終更新日	12 Jun 2024

今後の成長に関する最新情報

Recent updates

Viridian Therapeutics: Key Catalysts Coming In The Second Half Of The Year

Jun 12

Is Viridian Therapeutics (NASDAQ:VRDN) Using Debt Sensibly?

May 28

Despite Lacking Profits Viridian Therapeutics (NASDAQ:VRDN) Seems To Be On Top Of Its Debt

Sep 12

Is There An Opportunity With Viridian Therapeutics, Inc.'s (NASDAQ:VRDN) 44% Undervaluation?

May 15

An Intrinsic Calculation For Viridian Therapeutics, Inc. (NASDAQ:VRDN) Suggests It's 49% Undervalued

Aug 22

Viridian Therapeutics Q2 2022 Earnings Preview

Aug 12

Viridian Therapeutics gets a new COO

Jun 23

Viridian Therapeutics (VRDN) Investor Presentation - Slideshow

Jun 08

業績と収益の成長予測

NasdaqCM:VRDN - アナリストの将来予測と過去の財務データ ( )USD Millions
日付	収益	収益	フリー・キャッシュフロー	営業活動によるキャッシュ	平均アナリスト数
12/31/2026	115	-199	-236	-214	10
12/31/2025	0	-270	-212	-260	13
12/31/2024	0	-230	-178	-196	14
3/31/2024	0	-218	-168	-167	N/A
12/31/2023	0	-238	-185	-184	N/A
9/30/2023	0	-217	-181	-180	N/A
6/30/2023	1	-198	-163	-162	N/A
3/31/2023	2	-172	-136	-135	N/A
12/31/2022	2	-130	-95	-94	N/A
9/30/2022	2	-113	-77	-76	N/A
6/30/2022	1	-98	-68	-68	N/A
3/31/2022	2	-87	-65	-64	N/A
12/31/2021	3	-79	-55	-55	N/A
9/30/2021	3	-141	-48	-47	N/A
6/30/2021	3	-133	-41	-41	N/A
3/31/2021	2	-121	-33	-33	N/A
12/31/2020	1	-111	-30	-30	N/A
9/30/2020	2	-30	-28	-28	N/A
6/30/2020	3	-36	-32	-32	N/A
3/31/2020	5	-38	-33	-33	N/A
12/31/2019	4	-42	-36	-36	N/A
9/30/2019	4	-42	-37	-36	N/A
6/30/2019	4	-40	-34	-34	N/A
3/31/2019	4	-40	-32	-31	N/A
12/31/2018	8	-33	-27	-27	N/A
9/30/2018	9	-29	-26	-26	N/A
6/30/2018	10	-26	-25	-25	N/A
3/31/2018	8	-24	-28	-27	N/A
12/31/2017	4	-27	N/A	-28	N/A
9/30/2017	3	-26	N/A	-24	N/A
6/30/2017	3	-24	N/A	-21	N/A
3/31/2017	3	-21	N/A	-19	N/A
12/31/2016	3	-17	N/A	-15	N/A
9/30/2016	4	-17	N/A	-14	N/A
12/31/2015	5	-16	N/A	-13	N/A
12/31/2014	8	-6	N/A	-8	N/A

アナリストによる今後の成長予測

収入対貯蓄率: VRDN今後 3 年間、利益が出ない状態が続くと予測されています。

収益対市場: VRDN今後 3 年間、利益が出ない状態が続くと予測されています。

高成長収益: VRDN今後 3 年間、利益が出ない状態が続くと予測されています。

収益対市場: VRDNの収益 ( 67.9% ) US市場 ( 8.4% ) よりも速いペースで成長すると予測されています。

高い収益成長: VRDNの収益 ( 67.9% ) 20%よりも速いペースで成長すると予測されています。

一株当たり利益成長率予想

将来の株主資本利益率

将来のROE: VRDNの自己資本利益率が 3 年後に高くなると予測されるかどうかを判断するにはデータが不十分です

Viridian Therapeutics 将来の成長

Future 基準チェック /26

主要情報

今後の成長に関する最新情報

Consensus revenue estimates increase by 21%

Price target decreased by 7.3% to US$36.50

Consensus revenue estimates decrease by 15%, EPS upgraded

Price target decreased by 8.0% to US$40.07

Price target decreased by 10% to US$41.36

Consensus revenue estimates increase by 18%

Recent updates

Viridian Therapeutics: Key Catalysts Coming In The Second Half Of The Year

Is Viridian Therapeutics (NASDAQ:VRDN) Using Debt Sensibly?

Consensus revenue estimates increase by 21%

Price target decreased by 7.3% to US$36.50

First quarter 2024 earnings: EPS exceeds analyst expectations while revenues lag behind

Viridian Therapeutics, Inc., Annual General Meeting, Jun 17, 2024

New minor risk - Share price stability

New major risk - Shareholder dilution

Full year 2023 earnings: EPS and revenues miss analyst expectations

Viridian Therapeutics, Inc. Appoints Jennifer Tousignant as Chief Legal Officer

Viridian Therapeutics, Inc. has filed a Follow-on Equity Offering.

Viridian Therapeutics, Inc. Announces Executive Changes

Consensus revenue estimates decrease by 15%, EPS upgraded

Price target decreased by 8.0% to US$40.07

Third quarter 2023 earnings: EPS exceeds analyst expectations while revenues lag behind

Viridian Therapeutics, Inc. announced that it has received $185.000072 million in funding from a group of investors

Viridian Therapeutics, Inc. Announces the Resignation of Scott Myers as a Member of the Board of Directors

Price target decreased by 10% to US$41.36

Viridian Therapeutics, Inc. announced that it expects to receive $185.000072 million in funding from a group of investors

Viridian Therapeutics, Inc. Appoints Sarah Gheuens to its Board of Directors

Viridian Therapeutics, Inc. Announces Executive Changes

Despite Lacking Profits Viridian Therapeutics (NASDAQ:VRDN) Seems To Be On Top Of Its Debt

Second quarter 2023 earnings: EPS and revenues miss analyst expectations

Consensus revenue estimates increase by 18%

Viridian Therapeutics, Inc. Announces Positive Data from Ongoing Phase 1/2 Trial Evaluating VRDN-001 in Patients with Chronic Thyroid Eye Disease (TED)

Viridian Therapeutics, Inc. Announces Positive Data from Ongoing Phase 1/2 Trial Evaluating VRDN-001 in Patients with Chronic Thyroid Eye Disease (TED)

Is There An Opportunity With Viridian Therapeutics, Inc.'s (NASDAQ:VRDN) 44% Undervaluation?

First quarter 2023 earnings: EPS and revenues miss analyst expectations

Is Viridian Therapeutics (NASDAQ:VRDN) Weighed On By Its Debt Load?

President recently bought US$101k worth of stock

Consensus revenue estimates fall by 35%

President recently bought US$160k worth of stock

Full year 2022 earnings: EPS and revenues miss analyst expectations

High number of new and inexperienced directors

Viridian Therapeutics, Inc. Appoints Scott Myers as Chief Executive Officer

Price target increased by 9.1% to US$47.08

Chief Medical Officer exercised options and sold US$708k worth of stock

Viridian Therapeutics, Inc. Announces Positive Data from Ongoing Phase 1/2 Trial Evaluating Low Dose VRDN-001 in Patients with Thyroid Eye Disease (Ted)

Does Viridian Therapeutics (NASDAQ:VRDN) Have A Healthy Balance Sheet?

Viridian Therapeutics Announces First Patient Enrolled in the ‘Thrive’ Phase 3 Trial in Patients with Thyroid Eye Disease

Consensus revenue estimates increase by 162%

Third quarter 2022 earnings: EPS and revenues exceed analyst expectations

High number of new and inexperienced directors

Viridian Therapeutics, Inc Announces Positive Data from Ongoing Phase 1/2 Trial Evaluating VRDN-001 in Patients with Thyroid Eye Disease (TED)

Viridian Therapeutics, Inc. to Report Q3, 2022 Results on Nov 14, 2022

Viridian Therapeutics, Inc. Presents Positive Clinical Data from Ongoing VRDN-001 Phase 1/2 Trial in Active Thyroid Eye Disease (TED) Patients During Late-Breaking Presentations at the American Thyroid Association (ATA) 91st Annual Meeting

Viridian: Excellent Early Data, Strong Cash, Great Strategy, Large Market

Viridian Therapeutics board compensation committee approves inducement grants

Consensus forecasts updated

An Intrinsic Calculation For Viridian Therapeutics, Inc. (NASDAQ:VRDN) Suggests It's 49% Undervalued

Second quarter 2022 earnings: Revenues exceed analysts expectations while EPS lags behind

Viridian Therapeutics, Inc. Announces Positive Initial Clinical Data from Ongoing Phase 1/2 Trial Evaluating VRDN-001 in Patients with Thyroid Eye Disease (TED)

Price target increased to US$39.22

Viridian Therapeutics Q2 2022 Earnings Preview

Viridian Therapeutics, Inc. to Report Q2, 2022 Results on Aug 15, 2022

Viridian Therapeutics Appoints Carrie Melvin as Chief Operating Officer

Viridian Therapeutics gets a new COO

Co-Founder notifies of intention to sell stock

First quarter 2022 earnings: EPS exceeds analyst expectations while revenues lag behind

Viridian Therapeutics, Inc. to Report Q1, 2022 Results on May 12, 2022

High number of new and inexperienced directors

CEO, President & Director notifies of intention to sell stock

Viridian Therapeutics, Inc. announced that it expects to receive $75 million in funding from Hercules Capital, Inc.

Consensus forecasts updated

Full year 2021 earnings: EPS exceeds analyst expectations while revenues lag behind

Viridian Therapeutics, Inc. to Report Q4, 2021 Results on Mar 10, 2022

Viridian Therapeutics Announces FDA Clearance of Investigational New Drug Application to Initiate Clinical Development of VRDN-002

Viridian Therapeutics Submits Investigational New Drug Application for VRDN-002 to the U.S. Food and Drug Administration

Viridian Therapeutics Announces First Subject Dosed in Phase 1/2 Clinical Trial of VRDN-001 for Thyroid Eye Disease (TED)